Skip to main content
. 2022 Sep 20;12:988680. doi: 10.3389/fonc.2022.988680

Figure 10.

Figure 10

(A–L) IC50 for small molecule drugs in high and low risk populations.(A): Bosutinib, (B): Cisplatin, (C): Cytarabine, (D): Gefitinib, (E): Gemcitabine, (F): Imatinib, (G): Lapatinib, (H): Lenalidomide, (I): Nilotinib, (J): Paclitaxel, (K): Pazopanib, (L): Sunitinib. IC50, half maximum inhibitory concentration.